Predicting maximal oxygen uptake from the 6 min walk test in patients with heart failure

Pallav Deka¹, Bunny J. Pozehl², Dola Pathak³, Mark Williams⁴, Joseph F. Norman⁵, Windy W. Alonso² and Tiny Jaarsma⁶*

¹College of Nursing, Michigan State University, East Lansing, MI, USA; ²College of Nursing, University of Nebraska Medical Center, Omaha, NE, USA; ³Department of Statistics and Probability, Michigan State University, East Lansing, MI, USA; ⁴Division of Cardiology, Creighton University School of Medicine, Omaha, NE, USA; ⁵College of Allied Health Professions, University of Nebraska Medical Center, Omaha, NE, USA; ⁶Department of Social and Welfare Studies, Faculty of Health Sciences, Linköping University, Linköping, Sweden

Abstract

Aims  A cardiopulmonary exercise (CPX) test is considered the gold standard in evaluating maximal oxygen uptake. This study aimed to evaluate the predictive validity of equations provided by Burr et al., Ross et al., Adedoyin et al., and Cahalin et al. in predicting peak VO₂ from 6 min walk test (6MWT) distance in patients with heart failure (HF).

Methods and Results  New York Heart Association Class I–III HF patients performed a maximal effort CPX test and two 6MWTS. Correlations between CPX VO₂ peak and the predicted VO₂ peak, coefficient of determination (R²), and mean absolute percentage error (MAPE) scores were calculated. P-values were set at 0.05. A total of 106 participants aged 62.5 ± 11.5 years completed the tests. The mean VO₂ peak from CPX testing was 16.4 ± 3.9 mL/kg/min, and the mean 6MWT distance was 419.2 ± 93.0 m. The predicted mean VO₂ peak (mL/kg/min) by Burr et al., Ross et al., Adedoyin et al., and Cahalin et al. was 22.8 ± 8.8, 14.6 ± 2.1, 8.30 ± 1.4, and 16.6 ± 2.8. A significant correlation was observed between the CPX test VO₂ peak and predicted values. The mean difference (0.1 mL/kg/min), R² (0.97), and MAPE (0.14) values suggest that the Cahalin et al. equation provided the best predictive validity.

Conclusions  The equation provided by Cahalin et al. is simple and has a strong predictive validity, and researchers may use the equation to predict mean VO₂ peak in patients with HF. Based on our observation, equations to predict individual maximal oxygen uptake should be used cautiously.

Keywords  Heart failure; Cardiopulmonary testing; 6 min walk test; Prediction; Peak VO₂

Introduction

Maximal oxygen uptake (VO₂ max) is considered the gold standard for measuring aerobic exercise capacity. Clinically, peak oxygen consumption (VO₂ peak) is often used as a surrogate for VO₂ max for patient populations. VO₂ peak is determined by cardiopulmonary exercise (CPX) testing, typically performed on a treadmill or bicycle ergometer, with incremental increases in exercise workloads to maximal effort, generally limited by symptoms or fatigue. Results from CPX testing are used to assess exercise tolerance, develop exercise prescriptions, evaluate treatment efficacy, and investigate exercise-induced adaptations of the oxygen transport and utilization system. maximal effort CPX testing is generally well tolerated by patients with cardiovascular diseases. In patients with heart failure (HF), the landmark HF-ACTION study and other meta-analyses reported no adverse effects of CPX testing in HF with both preserved and reduced ejection fraction. However, with greater than minimal risk involved, it is recommended that maximal effort CPX testing in patients with clinically stable HF be performed in a laboratory setting supervised by trained medical personnel. Because the test is expensive and the required infrastructure and qualified personnel may not be readily available, alternate forms of testing to measure functional capacity are often used. For patients with HF, the sub-maximal 6 min walk...
test (6MWT), with established reliability and validity, is commonly recommended as an alternate choice.\(^6,9\)

The 6MWT is cost-effective, easy to administer, and well tolerated.\(^10\) It is used as an outcome measure to determine activity of daily living\(^11\) and quality of life outcomes\(^12–14\) and in clinical practice to evaluate treatment response and exercise capacity, predict frailty, and evaluate mortality and 30 day re-hospitalization rate in patients with HF.\(^15–17\) With 6MWT distance correlating with VO\(_2\)* values,\(^18\) its ability to accurately predict physiologic change in VO\(_2\) peak in patients with HF can have practical utility.

Over the years, various equations to predict a VO\(_2\) max or VO\(_2\) peak from a 6MWT have been proposed. In this study, we evaluated each of the four prediction equations developed by Burr et al.,\(^19\) Ross et al.,\(^20\) Adedoyin et al.,\(^21\) and Cahalin et al.\(^22\) and assessed their ability to accurately predict VO\(_2\) peak from the 6MWT in patients with HF. The equations, as described in the Methods section, are different from each other in how they were formulated, the population they were tested on, and the number of variables required to predict VO\(_2\) peak. These equations were specifically selected for their simplicity and ease of use whereby the estimation of VO\(_2\) peak is calculated from easily assessable information such as age, sex, weight, resting heart rate (HR), and 6MWT distance. Cahalin et al.\(^22\) provided several prediction equations from their study of patients with HF. We excluded the equations that required values of forced vital capacity, forced expiratory volume, cardiac index, rate pressure product, pulmonary artery pressure, or left ventricular ejection fraction for computing peak VO\(_2\), as these values may not be readily available or would require additional testing. Additionally, treatment guidelines for the management of HF, including the use of beta-blockers and other drugs that impact cardiac function, have undergone modifications in the past 15 years.\(^23–30\) Consequently, because each of the study equations were developed before more recent treatment modifications came into effect, there is need to re-evaluate their ability to accurately predict peak VO\(_2\) in stable patients with HF. Therefore, the purpose of the study was to evaluate and compare the predictive validity of equations provided by Burr et al.,\(^19\) Ross et al.,\(^20\) Adedoyin et al.,\(^21\) and Cahalin et al.\(^22\) in predicting peak VO\(_2\) from 6MWT distance in patients with stable HF.

**Methods**

This secondary analysis utilizes baseline measures of peak VO\(_2\) from CPX testing and 6MWT data from the National Institutes of Health-funded longitudinal study titled Heart Failure Exercise And Resistance Training (HEART) Camp (R01-HL112979). The two-site HEART Camp study was a facility-based randomized controlled intervention designed to improve adherence to the recommended 150 min/week of aerobic exercise in patients with HF. The investigation conforms with the principles outlined in the Declaration of Helsinki and was approved by the Institutional Review Board at the University of Nebraska Medical Center (Chairperson: Dr. Bruce Gordon; IRB# 608-11-FB, approved 14 December 2011). Participants signed informed consent before participation. The primary study protocol and its results have been published.\(^31,32\) For this study, we use data from the Lincoln (NE) site.

**Subjects**

A total of 119 participants diagnosed with HF with New York Heart Association (NYHA) scale I–III were recruited for the study. Of these, 12 participants dropped out after enrolment or did not complete the second 6MWT, leaving a sample size of 106. Power analysis was performed using G* power.\(^33\) The post-hoc t-test for correlational statistic (VO\(_2\) and 6MWT) using a sample size of 106, \(\alpha\) of 0.05, and a moderate effect size of 0.30 gave a power of 0.90. Participants were recruited from the Bryan Heart Clinic in Lincoln, Nebraska. Inclusion criteria for participation were (i) diagnosis of HF (Stage C chronic HF confirmed by echocardiography and clinical evaluation); (ii) 19 years of age or older; (iii) able to speak and read English; (iv) telephone access in-home; and (v) stable pharmacologic therapy per guidelines for past 30 days. Exclusion criteria included (i) clinical evidence of decompressed HF; (ii) unstable angina pectoris; (iii) myocardial infarction, coronary artery bypass surgery, or biventricular pacemaker <6 weeks prior; (iv) orthopaedic or neuromuscular disorders preventing participation in aerobic exercise and strength/resistance training; (v) participation in three times per week aerobic exercise during the past 8 weeks; (vi) cardiopulmonary stress test results that precluded safe exercise training; (vii) plans to move >50 miles from the exercise site within the next year; (viii) peak oxygen consumption >21 mL/kg/min in women and >24 mL/kg/min in men; and (ix) planned or current pregnancy. Additionally, per recommendations by Ross et al.,\(^20\) 6MWT distances >600 m were not considered for analysis. Their prediction equation underestimated VO\(_2\) peak in participants walking >600 m in the 6MWT. In our sample, one person walked a distance of 605 m. We excluded this value in the analysis.

**Experimental procedure**

The study was divided into two parts: (i) conducting a CPX test to evaluate VO\(_2\) peak and (ii) participants completing two 6MWTS to record distance covered in 6 min. These measurements were done during baseline testing for the HEART Camp study. Data were collected between 2013 and 2015.
The values from the 6MWT were used to predict the maximal oxygen uptake using the equations in Table 1.

i CPX test: On Day 1 of the study, participants performed a maximal effort CPX using a 10-stage ramp protocol to determine VO₂ peak. The test was conducted by an exercise specialist and supervised by a nurse practitioner/physician assistant/physician. The treadmill speed was started at 1 mile/h with 0% incline. Both the speed (max 3.3 miles/h) and incline (max 15%) were increased every 2 min until voluntary exhaustion or if HR, respiration, and/or physical appearance indicated peak effort. For patients who were not limited by symptoms, the respiratory exchange ratio was also assessed to determine maximal effort during the test. Rating of perceived exertion (RPE) was recorded at each stage of the test. Heart rhythm was monitored throughout the test.

ii 6MWT: Two 6MWTs were performed by each participant. The first test was performed on the day of the CPX test. Participants were given at least 3 h of rest after the CPX test before performing the 6MWT. Two baseline tests were performed in a 30 m long hallway as per the instructions provided by the American Thoracic Society. The second 6MWT was performed 7–10 days after the first 6MWT as per the protocol of the HEART Camp study. Participants vocalized their RPE using the Borg (6–20) scale at the end of the test. For the purpose of consistency, the best score of the two walks was used for analysis, as it is a better representation of the participant’s functional capacity than the mean score of the two testing results of the 6MWT.

iii Description of the prediction equations:

### Data analysis

Participants with atrial fibrillation were considered for analysis if their HRs were controlled for the past year with stable dosing of beta-blockers. Pearson’s correlations between the VO₂ peak achieved at maximal effort on the CPX test and the calculated VO₂ peak from three prediction equations were analysed to test for predictive validity. The mean differences and error estimates were calculated for the VO₂ peak from the CPX testing and the predicted VO₂ peak from the equations. If no mean difference was found between the two values, the predictive validity of the equations to predict peak VO₂ of patients belonging to different NYHA functional classes were tested. Bland–Altman plots were created to compare the standardized VO₂ measures. To evaluate the accuracy of the predictive equations against the observed values from CPX testing, coefficient of determination (R²) to explain the amount of variance in the VO₂ peak from CPX testing and mean absolute percentage error (MAPE) were calculated. A lower MAPE score indicates better predictive accuracy. IBM-SPSS 25 and R 3.6.2 were used to analyse the data. The P-values were set at 0.05.

### Data availability

The primary study associated is available at https://clinicaltrials.gov/ (study identifier NCT01658670).

### Results

With 12 participants dropping out of the study before completing the second 6MWT, and one participant walking >600 m during the 6MWT, we were left with a final sample size of 106 participants. No significant difference was observed in the baseline characteristics of the participants who dropped out and the sample included for analysis. The test–retest reliability of the two 6MWT test was 0.94. The mean age of the participants in the study was 62.4 ± 11.4 years. Of the 106 participants, 65 were men and 41 women. The clinical characteristics included ejection fraction (40.4 ± 10.6%), months to HF diagnosis (61.1 ± 64.9), ischaemic cardiomyopathy (33%), and HF with reduced ejection fraction (87.7%). The sample consisted of four NYHA Functional Class I, 72 NYHA Functional Class II, and 30 NYHA Functional Class III patients. Descriptive

### Table 1 Description of the prediction equations

| Author          | Equation                                      | Population/data source                      |
|-----------------|-----------------------------------------------|---------------------------------------------|
| Burr et al. (2011)¹⁹ | VO₂ max = 70.161 + 0.023 * 6MWT (m) – 0.276 * weight (kg) – 6.79 * sex (M = 0; F = 1) – 0.193 * resting HR (b.p.m.) – 0.191 * age (years) | Tested on healthy middle-aged individuals   |
| Ross et al. (2010)²⁰ | VO₂ peak = 4.948 + 0.023 * mean 6MWT distance (m) | Data from the literature involving studies on HF and chronic obstructive pulmonary disease patients |
| Adedoyin et al. (2010)²¹ | VO₂ = 0.0105 × distance (m) + 0.0238 age (years) 0.03085 weight (kg) + 5.598 | NYHA Class II–III HF patients              |
| Cahalin et al. (1996)²¹ | VO₂ peak = 0.03 * distance (m) + 3.98 | Advanced symptomatic HF patients            |

CPX, cardiopulmonary exercise; F, female; HR, heart rate; M, male; NYHA, New York Heart Association; VO₂, oxygen uptake.
statistics including age, height, weight, HR, and 6MWT distance are described in Table 2.

The results (mean ± standard deviation; range) of VO2 peak from CPX testing and estimated VO2 peak (mL/kg/min) from the four prediction equations are CPX (16.5 ± 3.9; 7.0–26); Burr et al.19 (22.8 ± 8.8; −10 to 41); Ross et al.20 (14.6 ± 2.1; 8.2–18.8); Adedoyin et al.21 (8.03 ± 1.4; 3.6–11.6); and Cahalin et al.22 (16.6 ± 2.8; 8.2–22.1). Mean difference between VO2 peak from CPX testing and predicted VO2 peak was as follows: Burr et al.19 = 6.3, Ross et al.20 = −1.9, Adedoyin et al.21 and Cahalin et al.22 = 0.10. The Burr et al.19 (r = 0.48, P < 0.0001; R2 = 0.90) and Adedoyin et al.21 (r = 0.61; P < 0.0001; R2 = 0.96) equations showed a moderate correlation, while the Ross et al.20 (r = 0.75, P < 0.0001; R2 = 0.98) and Cahalin et al.22 (r = 0.75, P < 0.0001; R2 = 0.98) equations strongly correlated with the mean VO2 peak values from CPX testing. MAPE scores for Burr et al.19, Ross et al.20, Adedoyin et al.21, and Cahalin et al.22 were 0.56, 0.15, 0.48, and 0.14, respectively. Figure 1 reflects the ordered CPX VO2 peak values vs. predicted individual VO2 peak values from the four equations. Figures 2 and 3 show the association between CPX VO2 peak values and predicted VO2 peak from the three equations using Bland–Altman and scatter plots.

We did not find a significant difference (P = 0.58) between CPX VO2 peak and calculated predicted VO2 peak with the Cahalin et al.22 equation, while significant mean differences (P < 0.001) were observed using the other equations. Therefore, the Cahalin et al.22 equation was further analysed to predict VO2 by NYHA functional class. The predicted values were compared with the CPX values (Table 3). For this analysis, the four NYHA Class I participants were included with the NYHA Class II participants. Mean difference, standard error, and significant correlation (r) categorized by NYHA classes included Class I and II combined (−0.22, 0.27; r = 0.63) and Class III (−0.86; 0.3; r = 0.67). No significant differences were observed within the NYHA classes.

### Discussion

The results from our study show that while the four equations were able to explain ≥90% of the variance present in the peak VO2 values from CPX testing, there was a difference in their predictive ability as measured by MAPE. Mean differences show that the predicted VO2 peak using the four equations either grossly overestimated (Burr et al.19), grossly underestimated (Adedoyin et al.21), slightly underestimated (Ross et al.20), or closely predicted (Cahalin et al.22) the peak VO2 as observed from CPX testing. The Bland–Altman (Figure 2) and scatter plots in (Figure 3) show that the individual scores

| Table 2 Mean, SD, and range for age, height, weight, resting heart rate, and 6 min walk test distance of participants (n = 106) |
|-----------------------------------------------|
| **Age (years)** | **Height (cm)** | **Weight (kg)** | **Resting HR (b.p.m.)** | **6MWT (m)** |
|-----------------|-----------------|-----------------|-------------------------|---------------|
| Mean            | 62.4            | 172.4           | 102.95                  | 72.68         | 419.2         |
| SD              | 11.4            | 10.1            | 25.68                   | 12.67         | 93.0          |
| Range           | 25–84           | 150–172.4       | 56.4–206.4              | 41–109        | 141–600       |

**Figure 1** Ordered cardiopulmonary exercise (CPX) VO2 peak values (y-axis) vs. predicted individual VO2 peak values from the three equations (x-axis).
predicted by each of the equations are spread out, which resulted in a moderate-to-strong correlation between the CPX and predicted peak VO\textsubscript{2} values. The equations with a larger mean difference between predicted and observed values showed a moderate correlation, while the equations with small differences in mean values showed a stronger correlation. When categorized by NYHA functional classes, the predicted values using the Cahalin \textit{et al.}\textsuperscript{22} equation showed a significant positive correlation with a small mean difference of \leq 1. Ross \textit{et al.}\textsuperscript{20} have stated that generalized equations may be useful for accurately estimating mean peak VO\textsubscript{2} values from mean 6 MWT distance scores, but they may not be accurate in making predictions for individual patients. From the spread seen in the scatter plots in our study, the opinion expressed by Ross \textit{et al.}\textsuperscript{20} is justified and can also be extended to the other prediction equations as well. Overall, when comparing the four equations using the predicted mean peak VO\textsubscript{2} and the MAPE scores, we found that the predictive ability of

---

**Figure 2** Bland–Altman plot for standardized VO\textsubscript{2} values [Burr \textit{et al.}\textsuperscript{19} vs. cardiopulmonary exercise (CPX); Ross \textit{et al.}\textsuperscript{20} vs. CPX; Cahalin \textit{et al.}\textsuperscript{21} vs. CPX].

**Figure 3** Scatter plot showing the association between VO\textsubscript{2} peak values from cardiopulmonary exercise (CPX) testing and VO\textsubscript{2} peak from the prediction equations.

**Table 3** Peak VO\textsubscript{2} (mean, median, standard deviation, mean difference, and standard error in mL/kg/min) and correlational values from cardiopulmonary exercise and predicted by New York Heart Association functional class using Cahalin \textit{et al.}\textsuperscript{21} equation

| NYHA Method | Mean | Median | SD  | Mean difference (standard error) | Correlation (r) |
|-------------|------|--------|-----|---------------------------------|-----------------|
| Class I and II (n = 76) | CPX | 17.5   | 17.7 | 3.5 | 0.22 (0.27) | 0.63*           |
|             | Cahalin equation | 17.3  | 17.4 | 2.5  |                |                 |
| Class III (n = 30) | CPX | 13.8   | 14.4 | 3.5  | −0.86 (0.3)  | 0.67*           |
|             | Cahalin equation | 14.48 | 14.63| 2.7  |                |                 |

* A significant correlation between actual CPX testing VO\textsubscript{2} peak and predicted VO\textsubscript{2} peak values at \( P = 0.05 \).
Cahalin et al.\textsuperscript{22} (0.1 mL/kg/min; MAPE = 0.14) equation was superior to that of the Burr et al.\textsuperscript{19} (6.8 mL/kg/min; MAPE = 0.54), Ross et al.\textsuperscript{20} (1.9 mL/kg/min; MAPE = 0.16), and Adedoyin et al.\textsuperscript{21} (–8.47 mL/kg/min; MAPE = 0.48) equations.

It is reported that the use of sub-maximal exercise tests to predict \( \text{VO}_2 \text{ max} \) may underestimate the actual \( \text{VO}_2 \text{ max} \). The 6MWT is generally considered a sub-maximal exercise test where participants do not reach their maximal exercise capacity and are also allowed to rest, if needed, during testing.\textsuperscript{10} As such, it can be assumed that predictions of \( \text{VO}_2 \text{ peak} \) values using the 6MWT distance will slightly underestimate the peak \( \text{VO}_2 \) values from CPX testing for a participant. This phenomenon was observed with the equation provided by Ross et al.\textsuperscript{20} While the Burr et al.\textsuperscript{19} equation grossly overestimated the mean \( \text{VO}_2 \) values from CPX testing, the results of the Adedoyin et al.\textsuperscript{21} equation, which grossly underestimated the observed mean peak \( \text{VO}_2 \) were surprising. With the equation formulated by testing a sample of stable NYHA Class II and III HF patients, we expected the Adedoyin et al.\textsuperscript{21} equation to be the most accurate in predicting peak \( \text{VO}_2 \) in our study. The gross inaccuracy may be explained by the difference in the samples between the two studies. Whereas our sample consisted of participants who were mostly Caucasian, the Adedoyin et al.\textsuperscript{21} study, done in Nigeria, although not described by the authors, most likely consisted mostly of Black population. Another important factor may be a difference in the medication management of HF. The use of beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and diuretics is part of the standard clinical therapy that our participants were provided as part of their usual care. Such therapy has been shown to improve functional capacity in patients with HF.\textsuperscript{24,29} This information along with observed \( \text{VO}_2 \text{ peak} \) from CPX testing is not reported in the Adedoyin et al.\textsuperscript{21} study. Our study also excluded participants with peak oxygen consumption >21 mL/kg/min in women and >24 mL/kg/min in men, which may contribute to the differences in peak \( \text{VO}_2 \) values from CPX testing. The differences found in the mean peak \( \text{VO}_2 \) values using the predicted equations may be explained by the participant demographics used to formulate these equations and the fact that the treatment of HF has undergone significant changes in the past 20 years.

The population that Ross et al.\textsuperscript{20} used to formulate their prediction equation included a diverse group of clinical patients that included HF patients. The equation proposed by Cahalin et al.\textsuperscript{22} was based on the testing of advanced, symptomatic HF patients, while our sample was composed of stable HF patients. Burr et al.\textsuperscript{19} developed their prediction equation based on their results from testing of healthy adults with ages ranging between 28 and 60 years. This may explain the gross overestimation in mean \( \text{VO}_2 \text{ peak} \) values for our clinical population when using the Burr et al.\textsuperscript{19} equation. The sample sizes in the four studies were different as well. Burr et al.\textsuperscript{19} had a sample size of 44; Ross et al.\textsuperscript{20} mostly used raw data from previously published research and had a sample size of 1083 that included 673 HF patients; Adedoyin et al.\textsuperscript{21} had a sample of 65 (30 men and 35 women); and Cahalin et al.\textsuperscript{22} had a sample size of 45. Our sample was similar to that of the Burr et al.\textsuperscript{19} and Adedoyin et al.\textsuperscript{21} studies where the majority of participants were Caucasian. The sample size and demographic are crucial components in developing prediction equations to accurately represent the population and to avoid errors.

Considering that HF patients, depending on the extent of their disease, can be severely compromised in their ability to exercise, it may be argued that predicted peak \( \text{VO}_2 \) values should be as accurate as possible or for safety purposes and it may be better to underestimate peak \( \text{VO}_2 \) by a small margin than risk grossly overestimating it. While it may be argued that HF patients have safely performed high-intensity exercise and the risk associated with overestimation of \( \text{VO}_2 \text{ peak} \) may be exaggerated, such programmes have been conducted in supervised settings, mostly with NYHA Class I–III HF patients and may not be appropriate for non-supervised performance in the community setting.\textsuperscript{39–42} Also, the HF-ACTION study found moderate-intensity exercise to be safe for patients with HF, and the current HF exercise guidelines from various organizations reflect the same.\textsuperscript{8,23,41,44} As such, the equation provided by Burr et al.\textsuperscript{19} developed from testing conducted on healthy adults, may not be appropriate for predicting peak \( \text{VO}_2 \) for patients with HF to prescribe exercise. It may also be argued that the RPE from 6MWT may in itself be adequate for developing exercise prescriptions for this population, as monitoring improvement in functional capacity pre-exercise to post-exercise training by use of a 6MWT is a common outcome measure. Although this may be true, the validity of these prediction equations needs to be established for accurate estimation of \( \text{VO}_2 \text{ peak} \) as they may also be used for research purposes. The strength of the study is that it takes into account four different equations developed by testing of diverse populations. Variations seen in our study in the predictive ability of the four equations should not be taken as a testament to their value or utility. Our sample consisted of stable HF patients who were mostly Caucasian, and our findings suggest the use of population-specific \( \text{VO}_2 \) prediction equations. We agree with Ross et al.\textsuperscript{20} in utilizing caution in using these predictions to estimate individual peak \( \text{VO}_2 \). We found the Cahalin et al.\textsuperscript{22} equation to be the most accurate in predicting mean peak \( \text{VO}_2 \) scores in patients with HF. The simplicity of the equation also justifies its use for practical purposes.

**Conclusions**

The use of a population-specific prediction equation to predict mean \( \text{VO}_2 \text{ peak} \) from mean 6MWT distance in
patients with HF may be a viable alternative to a CPX VO\textsubscript{2peak} exercise test when constraints of cost and available personnel cannot be overcome. However, with the possibility of grossly underestimating or overestimating exercise capacity, caution is advised when using these equations to predict peak VO\textsubscript{2} at an individual level. Based on our finding, for research purposes, where the mean peak VO\textsubscript{2} needs to be estimated, the Cahalin et al.\textsuperscript{22} equation may be used when the study sample is similar to that of Cahalin et al.\textsuperscript{22} and our study. Future studies should investigate the development of prediction equations that are more accurate in predicting peak VO\textsubscript{2} at the individual level.

**Conflict of Interest**

None declared.

**Funding**

The primary HEART Camp study was supported by NHLBI of the National Institutes of Health (award number RO1HL112979). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**References**

1. Mezzani A, Agostini P, Cohen-Solal A, Corrà U, Jegier A, Koudi E, Mazic S, Meurin P, Piepoli M, Simon A, Laethem CV, Vanhees L. Standards for the use of cardiopulmonary exercise testing for the functional evaluation of cardiac patients: a report from the Exercise Physiology Section of the European Association for Cardiovascular Prevention and Rehabilitation. *Eur J Cardiovasc Prev Rehabil* 2009; 16: 249–267.

2. American College of Sports Medicine. *ACSM's Exercise Testing and Prescription*. Lippincott Williams & Wilkins; 2017.

3. Swank AM, Horton J, Fleg JL, Fonarow GC, Ketyesian S, Goldberg L, Wolff G, Handberg EM, Bensimhon D, Illouz MC, Vest M, Ewald G, Blackburn G, Leiter E, Cooper L, Kraus WE, and for the HF-ACTION Investigators. Modest increase in peak VO\textsubscript{2} is related to better heart failure outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training. *Circ Heart Fail* 2012; 5: 579–585.

4. Pandey A, Parashar A, Kumbhani DJ, Agarwal S, Garg J, Kitzman D, Levine BD, Drazner M, Berry JD. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. *Circ Heart Fail* 2015; 8: 33–40.

5. Taylor RS, Davies EJ, Dalal HM, Davis R, Doherty P, Cooper C, Holland DJ, Jolly K, Smart NA. Effects of exercise training for heart failure with preserved ejection fraction: a systematic review and meta-analysis of comparative studies. *Int J Cardiol* 2012; 162: 6–13.

6. Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, Coke LA, Fleg JL, Forman DE, Gerber TC, Gulati M, Madan K, Rhodes J, Thompson PD, Williams MA, American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology, Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention. Exercise standards for testing and training: a scientific statement from the American Heart Association. *Circulation* 2013; 128: 873–934.

7. Balady GJ, Arena R, Siesjesma K, Myers J, Coke L, Fletcher GF, Forman D, Franklin B, Guazzi M, Gulati M, Ketyesian SJ, Lavelle JJ, Macko R, Mancini D, Milani RV, American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Peripheral Vascular Disease, Interdisciplinary Council on Quality of Care and Outcomes Research. Clinician’s guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. *Circulation* 2010; 122: 191–225.

8. Piepoli MF, Conraads V, Corra U, Dickstein K, Francis DP, Jaarsma T, McMurray J, Pieske B, Piotrowicz E, Schmid JP, Anker SD. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. *Eur J Heart Fail* 2011; 13: 347–357.

9. Ketyesian SJ, Squires RW, Ades PA, Thomas RJ. Incorporating patients with chronic heart failure into outpatient cardiac rehabilitation: practical recommendations for exercise and self-care counseling—a clinical review. *J Cardiopulm Rehabil Prev* 2014; 34: 223–229.

10. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 2002; 166: 111–117.

11. Enright PL. The six-minute walk test. *Respir Care* 2003; 48: 783–785.

12. Guyatt GH, Thompson PJ, Berman LB, Sullivan MJ, Townsend M, Jones NL, Pugsley SO. How should we measure function in patients with chronic heart and lung disease? *J Chronic Dis* 1985; 38: 517–524.

13. Lipkin DP, Scriven AJ, Crake T, Poole-Wilson PA. Six minute walking test for assessing exercise capacity in chronic heart failure. *Br Med J (Clin Res Ed)* 1986; 292: 653–655.

14. O'Keefe ST, Lye M, Donnellen C, Carmichael D. Reproducibility and responsiveness of quality of life assessment and six minute walk test in elderly heart failure patients. *Heart (British Cardiac Society)* 1998; 80: 377–382.

15. Boxer RS, Shah KB, Kenny AM. Frailty and prognosis in advanced heart failure. *Curr Opin Support Palliat Care* 2014; 8: 25–29.

16. Kommuri NV, Johnson ML, Koelling TM. Six-minute walk distance predicts 30-day readmission in hospitalized heart failure patients. *Arch Med Res* 2010; 41: 365–368.

17. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. *Can Med Assoc J* 1985; 132: 919–923.

18. Faggiano P, D'Aloia A, Guzani A, Giordano A. Assessment of oxygen uptake during the 6-minute walking test in patients with heart failure: preliminary experience with a portable device. *Am Heart J* 1997; 134: 203–206.

19. Burr JF, Bredin SS, Faktor MD, Warburton DE. The 6-minute walk test as a predictor of objectively measured exercise capacity in patients with chronic heart failure. *Circ Heart Fail* 2011; 4: 475–482.
aerobic fitness in healthy working-aged adults. *The Phys Sports Med* 2011; 39: 133–139.
20. Ross RM, Murthy JN, Wollak ID, Jackson AS. The six minute walk test accurately estimates mean peak oxygen uptake. *BMC Pulm Med* 2010; 10.
21. Agedoyin R, Adeyanju S, Balogun M, Adebayo RA, Akintomide AO, Akinwusi PO. Prediction of functional capacity during six-minute walk among patients with chronic heart failure. *Niger J Clin Pract* 2010; 13.
22. Cahanil LP, Mathier MA, Semigran MJ, Dec GW, DiSalvo TG. The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. *Chest* 1996; 110: 325–332.
23. Yancy CW, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2013; 62: e147–e239.
24. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld JA, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Am Coll Cardiol* 2017; 70: 776–803.
25. Beltran P, Palau P, Domínguez E, Faraldo M, Nunez E, Guri O, Mollar A, Sanchis J, Bayes-Genis A, Nunez J. Sacubitil/valsartan and short-term changes in the 6-minute walk test: a pilot study. *Int J Cardiol* 2018; 252: 136–139.
26. Poelzl G, Frick M, Lackner B, Huegel H, Alber HF, Mair J, Herold M, Schwarzacher SP, Pachinger O, Weidinger F. Short-term improvement in submaximal exercise capacity by optimized therapy with ACE inhibitors and beta blockers in heart failure patients is associated with restoration of peripheral endothelial function. *Int J Cardiol* 2006; 108: 48–54.
27. Mayer B, Holmer SR, Hengstenberg C, Lieb W, Pfeifer M, Schunkert H. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. *Int J Cardiol* 2005; 103: 182–186.
28. Hash TW, Prisant LM. β-Blocker use in systolic heart failure and dilated cardiomyopathy. *J Clinical Pharma* 1997; 37: 7–19.
29. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Euro J Heart Fail* 2016; 18: 891–975.
30. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2012; 33: 1787–1847.
31. Poehl BJ, Duncan K, Hertzig M, McGuire R, Norman JF, Artinian NT, Keteyian SJ. Study of adherence to exercise in heart failure: the HEART camp trial protocol. *BMC Cardiovasc Disord* 2014; 14.
32. Poehl BJ, McGuire R, Duncan K, Kupzyk K, Norman J, Artinian NT, Deka P, Krueger SK, Saval MA, Keteyian SJ. Effects of the HEART camp trial on adherence to exercise in patients with heart failure. *J Card Fail* 2018; 24: 654–660.
33. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G Power 3.1: tests for correlation and regression analyses. *Behav Res Methods* 2009; 41: 1149–1160.
34. Borg G. Perceived exertion as an indicator of somatic stress. *Scand J Rehabil Med* 1970; 2: 92–98.
35. Borg G. *Physical Performance and Perceived Exertion*. University of Lund; 1962.
36. Eston R, Lambird D, Sheppard K, Parfitt G. Prediction of maximal oxygen uptake in sedentary males from a perceptually regulated, sub-maximal graded exercise test. *J Sports Sci* 2008; 26: 131–139.
37. Fitchett MA. Predictability of VO₂ max from submaximal cycle ergometer and bench stepping tests. *Br J Sports Med* 1985; 19: 85–88.
38. Peserico CS, Mezarrova PV, Nogueira GA, Moraes SMF, Machado FA. Comparison between direct and indirect methods for the determination of the maximal oxygen uptake in female runners. *Revista Brasil de Med do Esport* 2011; 17: 270–273.
39. Wisloff U, Stylen A, Loennechen JP, Brulvod M, Haram PM, Tjonna AE, Helgerud J, Sirdahl SA, Lee SJ, Videm V, Bye A. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. *Circulation* 2007; 115: 3086–3094.
40. Nilsson BB, Westheim A, Risberg MA. Effects of group-based high-intensity aerobic interval training in patients with chronic heart failure. *Am J Cardiol* 2008; 102: 1361–1365.
41. Freyssin C, Verkindt C, Prieur F, Benach P, Maunier S, Blanc P. Cardiac rehabilitation in chronic heart failure: effect of an 8-week, high-intensity interval training versus continuous training. *Arch Phys Med Rehabil* 2012; 93: 1359–1364.
42. Chrysohoou C, Angelis A, Tsitsiakakis G, Spetsiotsi S, Nasis I, Tsiahrissis D, Rapakoulas P, Pitsavos C, Koulouris NG, Vogiatzis I, Dimitris T. Cardiovascular effects of high-intensity interval aerobic training combined with strength exercise in patients with chronic heart failure: A randomized phase III clinical trial. *Int J Cardiol* 2015; 179: 269–274.
43. Heart Failure Society of America. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. *J Card Fail* 2010; 16: 475–539.
44. O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA* 2009; 301: 1439–1450.